Curcumin/resveratrol boost FOLFOX efficacy

20 April 2008

Researchers from the USA-based Barbara Ann Karmanos Cancer Institute presented findings at the American Association for Cancer Research annual meeting in San Diego showing that adding curcumin or resveratrol to conventional chemotherapy could be effective in preventing the growth of chemoresistant colon cancer cells.

Curcumin, from the ginger family, is in the Indian curry spice turmeric and resveratrol is produced naturally by plants and is found in the skin of red grapes and in peanuts. Karmanos researchers investigated whether the addition of these non-toxic substances to a chemotherapy regimen of leucovorin, 5-fluorouracil and oxaliplatin (FOLFOX) would decrease the survival of colon cancer cells. Studies confirmed that both are effective and inhibit the growth of new colon cancer cells, with curcumin appearing to be superior, the scientists noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight